StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Trading Down 3.0 %

NASDAQ TRVN opened at $1.28 on Wednesday. Trevena has a 12 month low of $1.13 and a 12 month high of $12.73. The firm has a market capitalization of $1.11 million, a PE ratio of -0.03 and a beta of 1.05. The business’s 50-day moving average price is $1.65 and its two-hundred day moving average price is $2.21.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.